Is the development of drug-related lupus a contraindication for switching from one TNF alpha inhibitor to another?

Lupus

Volumn 18, Issue 2, 2009, Pages 169-171

  Kocharla, L ^a   Mongey, A B ^a  

^a UNIVERSITY OF CINCINNATI COLLEGE OF MEDICINE   (United States)

Author keywords

Adalimumab; Apoptosis; Drug related lupus; Infliximab; Pharmacokinetics

Indexed keywords

ADALIMUMAB; INFLIXIMAB; MONOCLONAL ANTIBODY; TUMOR NECROSIS FACTOR ALPHA;

ADULT; ARTICLE; CASE REPORT; CHEMICALLY INDUCED DISORDER; CROHN DISEASE; DRUG ANTAGONISM; HUMAN; MALE; SYSTEMIC LUPUS ERYTHEMATOSUS;

ADULT; ANTIBODIES, MONOCLONAL; CROHN DISEASE; HUMANS; LUPUS ERYTHEMATOSUS, SYSTEMIC; MALE; TUMOR NECROSIS FACTOR-ALPHA;

EID: 65349097943     PISSN: 09612033     EISSN: 14770962     Source Type: Journal    
DOI: 10.1177/0961203308093922     Document Type: Article

References (10)

1. Mongey, A-B, Hess, EV. Drug and environmental lupus: clinical manifestations and differences. In: Lahita, RG, (ed), Systemic lupus erythematosus. Academic Press, New York, USA; 2004. p. 893-904.
2. Ramos-Casals, M, Brito-Zeron, P, Munoz, S, et al. Autoimmune diseases induced by TNF-targeted therapies: analysis of 233 cases. Medicine 2007; 86: 242-251.
3. De Bandt, M, Sibilia, J, Le Loët, X, et al. Systemic lupus erythematosus induced by anti-tumour necrosis factor alpha therapy: a French national survey. Arthritis Res Ther 2005; 7: R545-R551.
4. Cush, JJ. Biological drug use: US perspectives on indications and monitoring. Ann Rheum Dis 2005; 64(Suppl. 4): 18-23.
5. Mongey, A-B, Hess, EV. Drug insight: autoimmune effects ofmedications-what's new. Nat Clin Pract Rheumatol 2008; 4: 136-144.
6. DeRycke, L, Baeten, D, Kruithof, E, Van den Bosch, F, Veys, EM, Dekeyser, F. Infliximab, but not etanercept, induces IgM antidouble-stranded DNA antibodies as main antinuclear reactivity: biologic and clinical implications in autoimmune arthritis. Arthritis Rheum 2005; 52: 2192-2201.
7. Tracey, D, Klareskog, L, Sasso, EH, Salfeld, JG, Tak, PP. Tumor necrosis factor antagonist mechanisms of action: A comprehensive review. Pharmacol Ther 2008; 117: 244-279.
8. St Clair, EW, Wagner, CL, Fasanmade, AA, et al. The relationship of serum infliximab concentration to clinical improvements in rheumatoid arthritis: results from ATTRACT, a multicenter, randomized, double-blind, placebo-controlled trial. Arthritis Rheum 2002; 46: 1451-1459.
9. Shen, C, Assche, GV, Colpaert, S, et al. Adalimumab induces apoptosis of human monocytes: a comparative study with infliximab and etanercept. Aliment Pharmacol Ther 2005; 21: 251-258.
10. Chaudhary, R, Butler, M, Playford, RJ, Ghosh, S. Anti-TNF antibody induced stimulated T lymphocyte apoptosis depends on the concentration of the antibody and etanercept induces apoptosis at rates equivalent to infliximab and adalimumab at 10 micrograms per ml concentration. Gastroenterology 2006; 130: A696.